Kerala Ayurveda Ltd. (KERALAYUR): Kerala Ayurveda Share Price Rises 9.30% Today on BSE

Kerala Ayurveda Ltd. traded at Rs 162.8, up 9.30% today. The micro-cap Healthcare stock has a market capitalisation of Rs 193.56 crore.

Kerala Ayurveda Share Price is in focus after the BSE-listed stock rose 9.30% to Rs 162.8 on 10 August 2026, compared with its previous close of Rs 148.95. With a market capitalisation of Rs 193.56 crore, Kerala Ayurveda Ltd. falls in the Micro Cap category, making this share price gain notable within today’s market action. The stock opened at Rs 162.85, touched a day high of Rs 162.85 and a day low of Rs 159.8, indicating that most of the move was sustained near the upper end of the intraday range.

For investors tracking Kerala Ayurveda Share Price Today, the supplied data confirms a clear price rise but does not establish a company-specific catalyst behind the move. What it does show is a sharp single-session re-rating in early trade, accompanied by turnover of Rs 0.03 crore and total traded volume of 1,925 shares on BSE. In a session where Stock Market Today screens often highlight top gainers by percentage change, the stock’s move was large enough to stand out within its market-cap segment.

From a broader stock analysis perspective, the current setup is mixed rather than one-sided. The price action is strong on the day, but the fundamental snapshot remains challenging, with negative earnings, negative return ratios and unusual negative valuation readings. That combination is exactly why Kerala Ayurveda Stock News is drawing attention on Univest today: the market move is strong, but investors still need to weigh price action against financial quality, sector benchmarks and peer positioning before interpreting today’s rally.

Kerala Ayurveda Ltd. (KERALAYUR) Share Price Today: Price Action Analysis

Kerala Ayurveda Ltd. (KERALAYUR) traded at Rs 162.8. versus the previous close of Rs 148.95, a rise of 9.3%. The stock opened at Rs 162.85, reached Rs 162.85, touched Rs 159.8. Reported volume was 1,925.

Kerala Ayurveda Ltd. (KERALAYUR) Fundamental Analysis

Kerala Ayurveda Ltd. was valued at a P/E ratio of -12.78x, a P/B ratio of -16x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -183.03% and ROCE of -0.45%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs -12.74, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Kerala Ayurveda Fundamental Analysis presents a far more complex picture than the day’s price action. The company’s market capitalisation stands at Rs 193.56 crore, placing it slightly above the same-industry median market cap of Rs 142.44 crore but well below the same-industry average of Rs 489.44 crore. That means the company is not among the smallest names in Pharmaceuticals & Drugs by industry standards, but it remains a micro-cap where price moves can be amplified.

On valuation, the stock’s P/E ratio is -12.78 and its P/B ratio is -16. These are not conventional positive valuation multiples and reflect a stressed earnings and net-worth profile rather than a normal low-multiple value case. Kerala Ayurveda Share Price therefore cannot be described as inexpensive simply because the ratio is low in numerical terms; the negative readings have to be interpreted in the context of losses and weak return metrics. EPS is -12.74, showing that earnings attributable to each share are currently negative. Dividend yield is 0, which means there is no current historical payout support in the supplied snapshot relative to the present share price.

Profitability ratios reinforce that weak underlying picture. ROE is -183.03, an extremely negative reading that indicates shareholder capital has not translated into positive returns in the recent measurement period. ROCE is -0.45, which shows capital employed has also not generated positive operating returns. In other words, Kerala Ayurveda Fundamental Analysis does not currently point to a profitable balance between capital use and earnings generation.

That contrast is what makes Kerala Ayurveda Stock Analysis interesting today. The stock is gaining sharply in the market, yet the financial snapshot remains under pressure. Negative EPS, a -12.78 P/E, a -16 P/B ratio, ROE of -183.03 and ROCE of -0.45 suggest that the recent share price rise is occurring despite weak reported return indicators, not because those metrics are already strong. For readers of Kerala Ayurveda Stock News on Univest, that means today’s move is best read as a market event first, with fundamentals still posing important questions about sustainability and financial quality. The ownership lens would normally help further, but the strongest additional context here comes from the sector benchmark and peer comparison.

Sector and Industry Context

Kerala Ayurveda Ltd. (KERALAYUR) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Kerala Ayurveda Ltd. (KERALAYUR) has a P/E ratio of -12.78x, which is below the benchmark median of 26.3x, a difference of -148.59%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Kerala Ayurveda Ltd. (KERALAYUR) has a ROE of -183.03%, which is below the benchmark median of 9.93%, a difference of -1,943.2%. Kerala Ayurveda Ltd. (KERALAYUR) has a ROCE of -0.45%, which is below the benchmark median of 12.96%, a difference of -103.47%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Kerala Ayurveda operates in the Healthcare sector and the Pharmaceuticals & Drugs industry, so the most relevant comparison is against the supplied same-industry benchmark set covering 140 companies. That benchmark shows Kerala Ayurveda’s valuation and return profile sits well below central industry measures, even though its market capitalisation is above the median size for the group.

The company’s P/E ratio of -12.78 compares with an industry median of 26.3 and an average of 80.76 across 104 companies with available P/E data. The benchmark range runs from 3.21 to 3417.8, which underlines how wide valuation dispersion can be in this industry. Kerala Ayurveda’s negative P/E sits outside the normal profitable range indicated by most sector constituents, which is a clear sign that the company’s earnings profile differs materially from the median pharmaceutical name.

The same pattern appears in book value and return metrics. Kerala Ayurveda’s P/B ratio is -16, against an industry median of 1.83 and average of 2.92 across 139 companies. The benchmark range stretches from -16 to 59.75, and Kerala Ayurveda is positioned at that lower extreme. On profitability, company ROE of -183.03 is far below the industry median of 9.93 and average of 7.45. Company ROCE of -0.45 is also lower than the median of 12.96 and average of 14.33. These are significant gaps, not marginal ones.

Market-cap context is more balanced. Kerala Ayurveda’s market capitalisation of Rs 193.56 crore is above the industry median of Rs 142.44 crore, though still far below the average of Rs 489.44 crore and nowhere near the upper end of Rs 3,032.97 crore. That tells investors the company is not unusually large for its segment, but it is also not the smallest fringe player in the benchmark set.

For anyone reading Kerala Ayurveda Share Price News Today, the sector view adds an important reality check. The stock’s price rise stands out in Share Market Today screens, but on benchmark valuation and return measures, the company sits below industry medians on P/E, P/B, ROE and ROCE. That does not negate the market move; it simply means the move is happening against a fundamentally weaker backdrop than the average Pharmaceuticals & Drugs company in the supplied universe.

Peer Comparison

Kerala Ayurveda Ltd. (KERALAYUR) has a P/E ratio of -12.78x compared with the displayed peer median of 31.12x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -183.03% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at -0.45% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Kerala Ayurveda Ltd. (KERALAYUR) has a market capitalisation of Rs 193.56 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Kerala Ayurveda’s peer set places it alongside listed Healthcare and Pharmaceuticals & Drugs names that are materially larger by market capitalisation. Among the supplied peers, Dishman Carbogen Amcis Ltd. has a market cap of Rs 3,032.97 crore, Hikal Ltd. stands at Rs 2,799.54 crore, Kwality Pharmaceuticals Ltd. at Rs 2,707.2 crore, Beta Drugs Ltd. at Rs 2,631.45 crore and Panacea Biotec Ltd. at Rs 2,531.49 crore. Kerala Ayurveda, at Rs 193.56 crore, is much smaller than all of them, which matters because smaller companies can show sharper price action with lower traded value.

On valuation, Kerala Ayurveda’s P/E of -12.78 is below the positive P/E readings of peers such as Dishman Carbogen Amcis at 31.12, Kwality Pharmaceuticals at 40.2, Beta Drugs at 63.43, Sai Parenteral’s at 176.28, NGL Fine-Chem at 44.02, Venus Remedies at 17.81 and Hester Biosciences at 15.11. The company’s negative P/B of -16 is also far below peer P/B levels like 0.45 for Dishman, 2.35 for Hikal, 8.18 for Kwality, 6.27 for Beta Drugs and 3.03 for Panacea Biotec.

Return ratios are equally stark. Kerala Ayurveda’s ROE of -183.03 is weaker than Dishman’s -2.89 and materially below positive peer readings such as 15.22 for Hikal, 28.21 for Kwality, 18.65 for Beta Drugs, 13.9 for Sai Parenteral’s and 27.9 for NGL Fine-Chem. ROCE at -0.45 is lower than Hikal’s 16.15, Kwality’s 26.35, Beta Drugs’ 22.17, Panacea’s 5.36, Solara’s 15.34, NGL Fine-Chem’s 33.91 and Hester Biosciences’ 14.12. Only Dishman’s ROCE at -0.26 comes close in weakness, and even that is still slightly better than Kerala Ayurveda’s reading.

This comparison does not explain why Kerala Ayurveda Share Price rose today, but it does show why the move is drawing scrutiny on Univest. Relative to peers, the company is smaller, carries weaker return metrics and trades on negative reported multiples. That means today’s share price gain is not being backed, at least in the supplied data, by superior profitability or scale versus comparable listed pharmaceutical names.

Why Investors Are Watching Kerala Ayurveda

Kerala Ayurveda Share Price is being watched because the stock has delivered a clear top-gainer style move within the micro-cap Healthcare space, while the underlying financial snapshot remains unusually weak. That mix of strong price action and difficult fundamentals naturally attracts attention in Market News and stock updates, especially when the move holds close to the intraday high.

• Verified price action: the stock rose 9.30% from Rs 148.95 to Rs 162.8, with the open and high both at Rs 162.85.
• Intraday tone: the day low of Rs 159.8 shows the stock stayed close to upper levels after the opening jump.
• Trading activity: total BSE volume was 1,925 shares with turnover of Rs 0.03 crore.
• Fundamental context: P/E at -12.78, P/B at -16, EPS at -12.74, ROE at -183.03 and ROCE at -0.45 remain weak.
• Sector position: the company’s valuation and return ratios sit below same-industry medians and averages.

What investors may monitor next is whether Kerala Ayurveda Share Price continues to hold above the previous close after this early move, and whether subsequent market updates show improving alignment between price momentum and financial performance. On Univest, the stock remains one to track for price action, market-cap positioning, benchmark comparisons and any change in the broader narrative around the company.

About Kerala Ayurveda

Kerala Ayurveda Ltd. is part of the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. That places the company in one of the most closely tracked parts of the Indian stock market, where investors often compare businesses on valuation, profitability and scale across a wide spectrum of listed healthcare names.

In market terms, Kerala Ayurveda is a micro-cap company with a market capitalisation of Rs 193.56 crore. Within the supplied same-industry benchmark of 140 companies, that makes it larger than the median market cap of Rs 142.44 crore but still much smaller than the average size of Rs 489.44 crore and far below the upper end of Rs 3,032.97 crore. This mid-lower positioning within the industry size band helps explain why Kerala Ayurveda Share Price can attract attention quickly when percentage moves become pronounced.

The available company context in the supplied data is limited to classification rather than business-segment detail, so the most reliable description is its industry placement. As a Pharmaceuticals & Drugs player inside Healthcare, the stock is naturally assessed alongside peer names such as Dishman Carbogen Amcis, Hikal, Kwality Pharmaceuticals, Beta Drugs, Panacea Biotec and Hester Biosciences. On Univest, that makes Kerala Ayurveda Stock News relevant not only as a standalone price move but also as part of a broader Healthcare and Pharma comparison framework where investors study Market Cap, P/E Ratio, P/B Ratio, ROE and ROCE side by side.

Track Kerala Ayurveda Share Price on Univest

Use Kerala Ayurveda Ltd. (KERALAYUR) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors following Kerala Ayurveda Share Price can use Univest to monitor live price changes, daily stock performance and broader market context in one place. Kerala Ayurveda Share Price Today, previous close, intraday range, market capitalisation and turnover help explain what happened in the session, while ratio data such as P/E, P/B, ROE, ROCE, EPS and dividend yield add fundamental perspective.

Univest also helps users compare Kerala Ayurveda with listed Healthcare and Pharmaceuticals peers, follow sector benchmark data, review 52-week levels when available and stay updated with Kerala Ayurveda Stock News, Kerala Ayurveda Share News and market-moving developments without turning a price update into an investment recommendation.

Frequently Asked Questions

Why is Kerala Ayurveda Share Price rising today?

Ans. Kerala Ayurveda Share Price rose because the stock moved up 9.30% in the session to Rs 162.8 from Rs 148.95. The supplied data confirms the price event and intraday strength, but it does not identify a company-specific catalyst.

What is Kerala Ayurveda Share Price Today?

Ans. Kerala Ayurveda Share Price Today is Rs 162.8, compared with the previous close of Rs 148.95. That means the stock is up Rs 13.85 or 9.30% in the current session, making it a notable micro-cap gainer.

What were the day high and day low for Kerala Ayurveda shares?

Ans. Kerala Ayurveda traded between a day low of Rs 159.8 and a day high of Rs 162.85. The stock also opened at Rs 162.85, showing that the opening level matched the session high in early trade.

On which exchange did Kerala Ayurveda record today’s move?

Ans. The reported move was recorded on BSE, where Kerala Ayurveda posted total traded volume of 1,925 shares. The supplied trading turnover for the session stands at Rs 0.03 crore, which is modest in absolute terms.

What is the market capitalisation of Kerala Ayurveda Ltd.?

Ans. Kerala Ayurveda Ltd. has a market capitalisation of Rs 193.56 crore. In the supplied same-industry benchmark, that is above the median market cap of Rs 142.44 crore, though still below the average of Rs 489.44 crore.

Is Kerala Ayurveda a large-cap or micro-cap stock?

Ans. Kerala Ayurveda is classified as a Micro Cap stock in the supplied market-cap category data. That classification is important because percentage price moves in micro-cap names can attract attention quickly on top gainer screens.

What does Kerala Ayurveda Fundamental Analysis show?

Ans. Kerala Ayurveda Fundamental Analysis shows weak reported profitability in the supplied snapshot. The company has a P/E of -12.78, P/B of -16, EPS of -12.74, ROE of -183.03, ROCE of -0.45 and dividend yield of 0.

How does Kerala Ayurveda compare with the Pharmaceuticals & Drugs industry?

Ans. Kerala Ayurveda’s supplied valuation and return ratios sit below industry central measures. Its P/E of -12.78 compares with a median of 26.3, while ROE of -183.03 and ROCE of -0.45 are below industry medians of 9.93 and 12.96.

How does Kerala Ayurveda compare with listed peers?

Ans. Kerala Ayurveda is far smaller than supplied peers such as Dishman Carbogen, Hikal and Kwality Pharmaceuticals. Its market cap is Rs 193.56 crore, versus more than Rs 2,000 crore for each listed peer included in the comparison set.

Why are investors tracking Kerala Ayurveda Stock News closely?

Ans. Investors are tracking Kerala Ayurveda Stock News because the stock delivered a 9.30% price rise while the supplied fundamental readings remain weak. That combination of strong market action and weak profitability makes the stock worth monitoring carefully.